Compare +50 510(k) Biocompatibility & Sterilization Providers
If your device touches the patient directly, indirectly, or through fluid pathways, biocompatibility and sterility evidence can control your 510(k) timeline. This directory page helps regulatory teams compare provider capabilities using criteria that map to FDA review expectations, not just lab marketing claims.
Fast path: start with your device-contact profile, sterilization modality, and shelf-life target, then use our linked calculators to estimate study scope and timeline before you request provider proposals.
Open Biocompatibility Matrix CalculatorWhy this provider category matters in 510(k)
Two avoidable problems regularly slow submissions: incomplete biological evaluation plans and sterilization packages that do not align with intended-use claims. In practice, teams often start with a test menu, but FDA reviewers evaluate your rationale chain: contact profile, risk rationale, endpoint selection, protocol quality, and data interpretation. A provider with strong project-management and regulatory communication can reduce additional information cycles by helping you frame studies around decision questions, not just pass/fail tables.
For EO, gamma, e-beam, steam, and related pathways, provider quality also influences rework risk. Validation planning should connect dose or cycle development, load configuration, packaging compatibility, and aging assumptions. If those pieces are sourced from disconnected vendors without a clear integration plan, your team absorbs the coordination burden and timeline drift increases.
Provider comparison framework
| Dimension | What to Ask | Why It Impacts Clearance |
|---|---|---|
| Regulatory fit | Can they map study design to FDA biocompatibility guidance and recognized standards? | Reduces gaps between lab output and reviewer expectations. |
| Method scope | Do they run required endpoints in-house or subcontract? | Subcontract chains can add hidden schedule risk. |
| Sterility package depth | Can they support process validation, residuals, packaging, and SAL rationale together? | Disconnected data packages trigger clarification rounds. |
| Protocol governance | Will protocols be reviewed jointly by technical and regulatory leads? | Improves first-pass protocol alignment with claims. |
| Turnaround reliability | Do they publish realistic lead-time windows and contingency plans? | Better forecasting for submission windows. |
| Reporting quality | Do reports explicitly connect results to safety rationale? | Cleaner traceability in your 510(k) narrative. |
Use the calculators before provider outreach
Biocompatibility Matrix
Estimate endpoint burden by contact type and duration so your RFQ scope is realistic.
Open toolSterility Validation Planner
Estimate validation effort by sterilization method, load families, and residual testing depth.
Open toolShelf-Life Sample Estimator
Forecast sample burden for accelerated aging and package integrity checkpoints.
Open toolHow to interpret proposals from testing providers
Proposal review should prioritize decision utility, not low sticker price. A cheaper quote can become expensive if endpoint assumptions are weak or if report framing does not support the claims in your substantial equivalence narrative. Ask each provider to annotate how each line item supports a specific submission claim. Ask for sample report sections, de-identified if needed, so your team can evaluate scientific narrative quality before contracting.
For biocompatibility, verify that chemistry, toxicology, and endpoint testing are tied to a coherent biological evaluation plan. For sterilization, verify your assumptions about product families, load worst-case rationale, and packaging interfaces are reflected explicitly in protocol design. If a provider cannot clearly discuss these links, you may be buying lab output without submission readiness.
Common pitfalls this directory workflow helps avoid
- Requesting full endpoint panels without risk-based rationale, leading to extra cost and schedule.
- Running sterilization validation before final packaging decisions stabilize.
- Treating aging studies as an afterthought rather than a linked label-claim program.
- Accepting reports that summarize results but do not explain why results support intended use.
- Mixing provider assumptions across studies without an integrated evidence map.
Internal linking map for your team
Use this directory as the hub page, then branch into detailed planning pages and back to your central 510(k) strategy:
- Biocompatibility Matrix Calculator for endpoint scope.
- Sterility Validation Calculator for method-specific plan sizing.
- Shelf-Life Calculator for aging and package sample burden.
- ISO 14971 Risk Analysis Guide for risk-file alignment.
- FDA 510(k) Submission Generator for end-to-end assembly.
Need a faster shortlist?
Build your project assumptions first, then compare providers against the same scope baseline to avoid apples-to-oranges proposals.
Build My 510(k) Plan